Tandem Diabetes Care Inc. (TNDM)
Tandem Diabetes Care Statistics
Share Statistics
Tandem Diabetes Care has 66.56M shares outstanding. The number of shares has increased by 2.92% in one year.
Shares Outstanding | 66.56M |
Shares Change (YoY) | 2.92% |
Shares Change (QoQ) | 1.21% |
Owned by Institutions (%) | 99.99% |
Shares Floating | 66.01M |
Failed to Deliver (FTD) Shares | 100 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 7.27M, so 10.94% of the outstanding shares have been sold short.
Short Interest | 7.27M |
Short % of Shares Out | 10.94% |
Short % of Float | 16.82% |
Short Ratio (days to cover) | 6.52 |
Valuation Ratios
The PE ratio is -24.55 and the forward PE ratio is -25.54. Tandem Diabetes Care's PEG ratio is 0.43.
PE Ratio | -24.55 |
Forward PE | -25.54 |
PS Ratio | 2.51 |
Forward PS | 0.8 |
PB Ratio | 8.96 |
P/FCF Ratio | 472.08 |
PEG Ratio | 0.43 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Tandem Diabetes Care.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.93, with a Debt / Equity ratio of 1.8.
Current Ratio | 2.93 |
Quick Ratio | 2.33 |
Debt / Equity | 1.8 |
Debt / EBITDA | -4.78 |
Debt / FCF | 94.83 |
Interest Coverage | -17.99 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $354.79K |
Profits Per Employee | $-36.24K |
Employee Count | 2,650 |
Asset Turnover | 0.97 |
Inventory Turnover | 3.01 |
Taxes
Income Tax | 4.16M |
Effective Tax Rate | -4.52% |
Stock Price Statistics
The stock price has increased by -45.49% in the last 52 weeks. The beta is 1.53, so Tandem Diabetes Care's price volatility has been higher than the market average.
Beta | 1.53 |
52-Week Price Change | -45.49% |
50-Day Moving Average | 22.92 |
200-Day Moving Average | 34.1 |
Relative Strength Index (RSI) | 33.57 |
Average Volume (20 Days) | 1.64M |
Income Statement
In the last 12 months, Tandem Diabetes Care had revenue of 940.2M and earned -96.03M in profits. Earnings per share was -1.47.
Revenue | 940.2M |
Gross Profit | 489.57M |
Operating Income | -99.13M |
Net Income | -96.03M |
EBITDA | -99.13M |
EBIT | -99.28M |
Earnings Per Share (EPS) | -1.47 |
Balance Sheet
The company has 69.23M in cash and 473.56M in debt, giving a net cash position of -404.33M.
Cash & Cash Equivalents | 69.23M |
Total Debt | 473.56M |
Net Cash | -404.33M |
Retained Earnings | -1.05B |
Total Assets | 967.66M |
Working Capital | 477.44M |
Cash Flow
In the last 12 months, operating cash flow was 24.23M and capital expenditures -19.23M, giving a free cash flow of 4.99M.
Operating Cash Flow | 24.23M |
Capital Expenditures | -19.23M |
Free Cash Flow | 4.99M |
FCF Per Share | 0.08 |
Margins
Gross margin is 52.07%, with operating and profit margins of -10.54% and -10.21%.
Gross Margin | 52.07% |
Operating Margin | -10.54% |
Pretax Margin | -9.77% |
Profit Margin | -10.21% |
EBITDA Margin | -10.54% |
EBIT Margin | -10.54% |
FCF Margin | 0.53% |
Dividends & Yields
TNDM does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for TNDM is $49, which is 190.6% higher than the current price. The consensus rating is "Buy".
Price Target | $49 |
Price Target Difference | 190.6% |
Analyst Consensus | Buy |
Analyst Count | 16 |
Stock Splits
The last stock split was on Oct 10, 2017. It was a backward split with a ratio of 1:10.
Last Split Date | Oct 10, 2017 |
Split Type | backward |
Split Ratio | 1:10 |
Scores
Altman Z-Score | 0.83 |
Piotroski F-Score | 4 |